Metastasis Clinical Trials

223 recruitingLast updated: June 17, 2026

There are 223 actively recruiting metastasis clinical trials across 37 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, Shanghai, China, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Metastasis Trials at a Glance

223 actively recruiting trials for metastasis are listed on ClinicalTrialsFinder across 6 cities in 37 countries. The largest study group is Not Applicable with 63 trials, with the heaviest enrollment activity in Houston, Shanghai, and New York. Lead sponsors running metastasis studies include Fudan University, Eli Lilly and Company, and Sun Yat-sen University.

Browse metastasis trials by phase

Treatments under study

About Metastasis Clinical Trials

Looking for clinical trials for Metastasis? There are currently 27 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastasis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastasis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 223 trials

Recruiting
Not Applicable

Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors

Skin CancerCutaneous TumorCutaneous Metastasis
Alpha Tau Medical LTD.80 enrolled2 locationsNCT04068155
Recruiting
Phase 1Phase 2

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

MetastasisCastration-Resistant Prostatic Cancer
Merck Sharp & Dohme LLC360 enrolled80 locationsNCT06863272
Recruiting
Phase 3

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,630 enrolled261 locationsNCT07213804
Recruiting

PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

Breast CancerBreast NeoplasmsNeoplasm Metastasis
AstraZeneca800 enrolled107 locationsNCT05573893
Recruiting
Phase 2

Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis

Brain Metastasis From Advanced HER2-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences102 enrolled1 locationNCT06839560
Recruiting

A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis.

Advanced Breast Cancer Brain Metastasis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences100 enrolled1 locationNCT06839547
Recruiting
Not Applicable

Hypnosis on Breathlessness Mastery in Patients With Persistent Dyspnea

Chronic Heart Failure (CHF)DyspneaCancer (With or Without Metastasis)+2 more
University Hospital, Geneva82 enrolled1 locationNCT07173348
Recruiting
Phase 1Phase 2

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Metastatic Renal Cell CarcinomaCarcinoma, Renal CellAdvanced Renal Cell Carcinoma+10 more
Pfizer224 enrolled109 locationsNCT07227415
Recruiting
Phase 1

Safety and Feasibility of Intraoperative Visualization With Cytalux in Children

Metastatic SarcomaOsteosarcomaPulmonary Metastasis+2 more
Ann & Robert H Lurie Children's Hospital of Chicago10 enrolled1 locationNCT06235125
Recruiting
Phase 3

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company920 enrolled327 locationsNCT07174336
Recruiting
Phase 3

A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

Colorectal NeoplasmsNeoplasm MetastasisGastrointestinal Neoplasms+2 more
Sun Yat-sen University280 enrolled1 locationNCT03303495
Recruiting
Phase 3

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled422 locationsNCT06119581
Recruiting
Phase 1

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Breast NeoplasmsStomach NeoplasmsColorectal Neoplasms+4 more
Eli Lilly and Company421 enrolled30 locationsNCT07114601
Recruiting
Not Applicable

Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases

Spinal cord compressionSpine MetastasesNeoplasm Metastasis+2 more
Henry Ford Health System60 enrolled1 locationNCT05023772
Recruiting
Phase 3

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Urinary Bladder NeoplasmsNeoplasm MetastasisCarcinoma, Transitional Cell
Eli Lilly and Company450 enrolled284 locationsNCT07218380
Recruiting
Not Applicable

Evaluation of the Evolution of Patient Care Within the Spinal Pathology Department

Spinal StenosisSpinal FractureVertebral Metastasis+1 more
University Hospital, Bordeaux15,000 enrolled1 locationNCT07627282
Recruiting
Phase 1

A Study of LY4175408 in Participants With Advanced Cancer

Triple-Negative Breast CancerCarcinoma, Non-Small Cell LungNeoplasm Metastasis+2 more
Eli Lilly and Company240 enrolled27 locationsNCT07046923
Recruiting
Phase 2

Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases

Brain MetastasisTNBC
Fudan University24 enrolled1 locationNCT07623577
Recruiting
Phase 1

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms
Eli Lilly and Company535 enrolled82 locationsNCT05614739
Recruiting

A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Low-volume Metastasis
Bayer100 enrolled1 locationNCT06661122